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Summary Minor alterations of immune, neuroendocrine, and autonomic function may be associated with the
chronic fatigue syndrome. o-3 fatty acids decrease the production of putative mediators of inflammation, including
interleukin-1, and tumor necrosis factor. Since interleukin-1 and tumor necrosis factor are the principal polypeptide
mediators of immunoregulation, reduced production of these cytokines by dietary supplementation with o-3, may be
a possible mechanism for the treatment of chronic fatigue syndrome. & 2002, Elsevier Science Ltd. All rights reserved.BACKGROUND
Chronic fatigue syndrome (CFS) is a disorder of unknown
etiology, consisting of prolonged or recurrent, debilitating
fatigue, and a multitude of symptoms including flu-like
symptoms, myalgia, weakness, arthralgia, low-grade fever,
sore throat, headache, sleep disturbances, swelling and
tenderness of lymph nodes and neurocognitive dysfunc-
tion for 6 months duration or longer (1±4). These symp-
toms are not caused by ongoing exertion; are not relieved
by rest; and result in a substantial reduction of previous
levels of occupational, educational, social, or personal
activities (1,4).
Chronic fatigue syndrome is common in primary care
patients and represents a considerable public health
burden (5).
Definitive diagnosis can be very challenging. Because
no markers objectively identify the presence of CFS,
diagnosis depends heavily on the presence of subjectiveReceived 28 November 2000
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is known (6).
The signs and symptoms, which include fatigue, mya-
lgia, and low-grade fever, are similar to those experienced
by patients infused with cytokines such as interleukin-1
(7). Minor alterations of immune, neuroendocrine, and
autonomic function may be associated with this syn-
drome (2,3). Findings show an activation of the immune
system, aberrations in several hypothalamic±pituitary
axes and involvement of other parts of the central nervous
system (8,9). These results suggest that an abnormality
exists in IL-1 beta secretion in CFS patients (7).
The o-3 triglycerides contain triglycerides of o-3 fatty
acids, eicosapentanoic acid and docosa hexanoic acid.
These long chain o-3 polyunsaturated fatty acids are pre-
cursors of eicosanoids in fish and when taken by man they
compete with the precursor arachidonic acid (10).
Omega-3 triglycerides derived from fish oils contain
triglycerides of eicosapentanoic acids and docosa hexa-
noic acids. They have vasodilator, antithrombotic, and
anti-inflammatory activity (10,11). Also, several non-
marine sources of o-3 fatty acids have been suggested as
possible alternatives for vegetarians and others who
cannot eat fish or take fish oils. These include walnuts
and walnut oils, wheat germ oil, rapeseed oil, soybeans,
butternuts, seaweed and purslane (12). Even so, very small249
250 Tamizi far and Tamiziincrements in intake may have health benefits, possibly
the result of a cumulative effect (13).
HYPOTHESIS
These fatty acids decrease the production of putative
mediators of inflammation, including platelet-activating
factor, interleukin-1, and tumor necrosis factor. Since
interleukin-1 and tumor necrosis factor are the principle
polypeptides mediator of immunoregulation, reduced
production of these cytokines may contribute to the
amelioration of immune system diseases in patients
receiving o-3 supplementation (14).
Interleukin-1 and tumor necrosis factor often act
synergistically e.g. on the synthesis of arachidonic acid
metabolites (13,14). Dietary supplementation with o-3
fatty acids reduces the amount of inducible production of
interlukin-1 and tumor necrosis factor. The reduced pro-
duction of IL-1a, IL-1b and TNF may contribute to the
decreased inflammatory responses reported in patients
receiving o-3 supplementation (14).
The mechanisms underlying the suppression of the
synthesis of interleukin-1 and tumor necrosis factor after
dietary supplementation with o-3 fatty acids remain
unknown. However alternation in the arachidonic acid
metabolites may explain in part the decrease production
of these two cytokines. The o-3 fatty acids induce changes
in both cyclo-oxygenase and lipo-oxygenase products.
One possible mechanism may be `competition with ara-
chidonic acid and decreased 5-lipoxygenase metabolites
such as leukoterine B4'. Supplementations with o-3 fatty
acids reduce the amount of leukoterine B4 production.
Thus a possible mechanism for this, decrease synthesis of
leukotrine B4 and generation of the biologically less-
active metabolite B5 from eicosapentanoic acid (4,10,13).
Shahar and colleagues found that o-3 fatty acids red-
uce the chemotactic responsiveness of neutrophils, inhibit
the production of leukotriene B4 from arachidonic acid
in leukocytes, and decrease the production of superoxide
anions in leukocytes and this is another possible
mechanism (13).
According to these data, we propose that the dietary
enriched with o-3 fatty acids could be a suitable regimen
for patients with chronic fatigue syndrome. Studies will
have to be performed to determine its efficacy and
appropriate dosage.
On the other hand, dietary supplementation involves
modulation and not suppression of cytokine production,
and the change in cytokine synthesis and cell mem-
brane phospholipids are reversible after cessation of
supplement (15).Medical Hypotheses (2002) 58(3), 249±250ACKNOWLEDGMENT
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